Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luye Enrolls Last Patient in Phase III Trial of Eylea Biosimilar

publication date: Mar 13, 2023

Yantai-based Luye Pharma has completed enrollment in a China Phase III clinical trial of BA9101, a VEGFR inhibitor that is a biosimilar to Regeneron’s Eylea. Eylea is approved in the US to treat several ophthalmic indications, including Neovascular (Wet) Age-Related Macular Degeneration (wAMD). Luye’s subsidiary, Boan Biotech, is running the trial together with its partner, Shanghai’s Ocumension, which acquired China commercialization rights to the drug. In a Phase I trial, BA9101 proved to be safe and well-tolerated. Luye paid $205 million in 2019 to acquire Boan and its portfolio of eight biosimilar candidates. More details....

Stock Symbol: (HK: 2186) (HK: 6955) (HK: 1477)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here